Altimmune, Inc. (ALT) - Latest Market Data

Price & Market Data

Price: $6.97

Daily Change: -$0.181 / 2.60%

Range: $6.75 - $7.41

Market Cap: $561,260,416

Volume: 4,336,342

Performance Metrics

1 Week: 23.13%

1 Month: 21.40%

3 Months: 16.89%

6 Months: -23.20%

1 Year: 6.79%

YTD: -4.02%

Company Details

Employees: 59

Sector: Health technology

Industry: Biotechnology

Country: United States

Details

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Selected stocks

Markel Group Inc. (MKL)

Marsh & McLennan Companies, Inc. (MMC)

MGIC Investment Corporation (MTG)